Enterococcus: An emerging pathogen in hospitals

Seminars in Respiratory and Critical Care Medicine

Volumn 24, Issue 1, 2003, Pages 49-59

  Weber, Stephen G ^a   Gold, Howard S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Critical care; Enterococcus; Hospital acquired; Infection control; VRE

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; KANAMYCIN; LINEZOLID; MINOCYCLINE; NETILMICIN; ORITAVANCIN; PENICILLIN DERIVATIVE; RAMOPLANIN; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; CRITICAL ILLNESS; DISEASE TRANSMISSION; ENTEROCOCCUS; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INTENSIVE CARE; INTESTINE FLORA; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; STRAIN DIFFERENCE;

EID: 0037330996     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37916     Document Type: Review

References (128)

1. Staphylococcus aureus resistant to vancomycin: United States, 2002. Morb Mortal Wkly Rep 2002;51:565-567
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001;29:404-421
3. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002;62:425-441
4. Facklam RR, Sahm DA. Enterococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. Washington, DC: American Society of Microbiology; 1995:308-314
5. Iwen PC, Kelly DM, Linder J, et al. Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period. Antimicrob Agents Chemother 1997;41:494-495
6. Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001;33:210-219
7. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990;3:46-65
8. Rice LB, Carias LL, Hutton-Thomas R, et al. Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 2001; 45:1480-1486
9. Rybkine T, Mainardi JL, Sougakoff W, et al. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcusfaecium with different levels of beta-lactam resistance. J Infect Dis 1998;178:159-163
10. Hanrahan J, Hoyen C, Rice LB. Geographic distribution of a large mobile element that transfers ampicillin and vancomycin resistance between Enterococcus faecium strains. Antimicrob Agents Chemother 2000;44:1349-1351
11. Coudron PE, Markowitz SM, Wong ES. Isolation of a beta-lactamase-producing, aminoglycoside-resistant strain of Enterococcusfaecium. Antimicrob Agents Chemother 1992;36: 1125-1126
12. Moellering RC. Antimicrobial susceptibility of enterococci: in vitro studies of the action of antibiotics alone or in combination. In: Bisno AL, ed. Treatment of Infective Endocarditis. New York: Grune & Stratton; 1981:81-96
13. Moellering RC Jr, Weinberg AN. Studies on antibiotic syngerism against enterococci, II: Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest 1971;50:2580-2584
14. Mederski-Samoraj BD, Murray BE. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis 1983;147:751-757
15. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-721
16. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-161
17. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1:57-58
18. Evers S, Quintiliani RJr, Courvalin P. Genetics of glycopeptide resistance in enterococci. Microb Drug Resist 1996;2:219-223
19. Lai KK, Kelley AL, Melvin ZS, et al. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Infect Control Hosp Epidemiol 1998;19:647-652
20. Bonilla HF, Zervos MA, Lyons MJ, et al. Colonization with vancomycin-resistant Enterococcusfaecium: comparison of a long-term-care unit with an acute-care hospital. Infect Control Hosp Epidemiol 1997;18:333-339
21. Elizaga ML, Weinstein RA, Hayden MK. Patients in long-term-care facilities: a reservoir for vancomycin-resistant enterococci. Clin Infect Dis 2002;34:441-446
22. Henning KJ, Delencastre H, Eagan J, et al. Vancomycin-resistant Enterococcusfaecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:848-854
23. Bonten MJ, Hayden MK, Nathan C, et al. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996;348:1615-1619
24. Jordens JZ, Bates J, Griffiths DT. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcusfaecium. J Antimicrob Chemother 1994;34:515-528
25. Ostrowsky BE, Venkataraman L, D'Agata EM, et al. Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. Arch Intern Med 1999;159:1467-1472
26. D'Agata EM, Jirjis J, Gouldin C, Tang YW. Community dissemination of vancomycin-resistant Enterococcus faecium. Am J Infect Control 2001;29:316-320
27. Endtz HP, van den Braak N, van Belkum A, et al. Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in the Netherlands. J Clin Microbiol 1997;35:3026-3031
28. van den Bogaard AE, Mertens P, London NH, Stobberingh EE. High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in the Netherlands: is the addition of antibiotics to animal feeds to blame? J Antimicrob Chemother 1997;40:454-456
29. Kim WJ, Weinstein RA, Hayden MK. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. J Infect Dis 1999;179:163-171
30. D'Agata EM, Li H, Gouldin C, Tang YW. Clinical and molecular characterization of vancomycin-resistant Enterococcusfaecium strains during establishment of endemicity. Clin Infect Dis 2001;33:511-516
31. Montecalvo MA, de Lencastre H, Carraher M, et al. Natural history of colonization with vancomycin-resistant Enterococcusfaecium. Infect Control Hosp Epidemiol 1995;16:680-685
32. Baden LR, Thiemke W, Skolnik A, et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term-care patients and the significance of "clearance." Clin Infect Dis 2001 33:1654-1660
33. Bonten MJ, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998;158:1127-1132
34. Puzniak LA, Mayfield J, Leet T, et al. Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit. Clin Infect Dis 2001;33:151-157
35. D'Agata EM, Gautam S, Green WK, et al. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin Infect Dis 2002;34:167-172
36. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925-1932
37. Wong MT, Kauffman CA, Standiford HC, et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001;33:1476-1482
38. Hachem R, Raad I. Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2002; 23:43-44
39. Mondy KE, Shannon W, Mundy LM. Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2001;33:473-476
40. Weinstein MR, Dedier H, Brunton J, et al. Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1999;29:361-366
41. Wells CL, Juni BA, Cameron SB, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995;21:45-50
42. D'Agata EM, Green WK, Schulman G, et al. Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis 2001;32: 23-29
43. Bakir M, Bova JL, Newell KA, et al. Epidemiology and clinical consequences of vancomycin-resistant enterococci in liver transplant patients. Transplantation 2001;72:1032-1037
44. Hayden MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis 2000;31:1058-1065
45. Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-1153
46. Beezhold DW, Slaughter S, Hayden MK, et al. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis 1997;24:704-706
47. Garbutt JM, Littenberg B, Evanoff BA, et al. Enteric carriage of vancomycin-resistant Enterococcusfaecium in patients tested for Clostridium difficile. Infect Control Hosp Epidemiol 1999;20:664-670
48. Katz KC, Gardam MA, Burt J, Conly JM. A comparison of multifaceted versus Clostridium difficile-focused VRE surveillance strategies in a low-prevalence setting. Infect Control Hosp Epidemiol 2001;22:219-221
49. Ray AJ, Hoyen CK, Das SM, et al. Undetected vancomycin-resistant Enterococcus stool colonization in a Veterans Affairs hospital using a Clostridium difficile-focused surveillance strategy. Infect Control Hosp Epidemiol 2002;23:474-477
50. Trick WE, Temple RS, Chen D, et al. Patient colonization and environmental contamination by vancomycin-resistant enterococci in a rehabilitation facility. Arch Phys Med Rehabil 2002;83:899-902
51. Ray AJ, Hoyen CK, Taub TF, Eckstein EC, Donskey CJ. Nosocomial transmission of vancomycin-resistant enterococci from surfaces. JAMA 2002;287:1400-1401
52. Noskin GA, Stosor V, Cooper I, et al. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol 1995;16: 577-581
53. Byers KE, Durbin LJ, Simonton BM, et al. Disinfection of hospital rooms contaminated with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1998; 19:261-264
54. Perry C, Marshall R, Jones E. Bacterial contamination of uniforms. J Hosp Infect 2001;48:238-241
55. Zachary KC, Bayne PS, Morrison VJ, et al. Contamination of gowns, gloves, and stethoscopes with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2001;22:560-564
56. Larson EL, Early E, Cloonan P, et al. An organizational climate intervention associated with increased handwashing and decreased nosocomial infections. Behav Med 2000;26: 14-22
57. D'Agata EM, Horn MA, Webb GF. The impact of persistent gastrointestinal colonization on the transmission dynamics of vancomycin-resistant enterococci. J Infect Dis 2002;185:766-773
58. Sakagami Y, Kajimura K. Bactericidal activities of disinfectants against vancomycin-resistant enterococci. J Hosp Infect 2002;50:140-144
59. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44:1-13
60. Tenorio AR, Badri SM, Sahgal NB, et al. Effectiveness of gloves in the prevention of hand carriage of vancomycin-resistant enterococcus species by health care workers after patient care. Clin Infect Dis 2001;32:826-829
61. Slaughter S, Hayden MK, Nathan C, et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1996;125:448-456
62. Puzniak LA, Leet T, Mayfield J, et al. To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci. Clin Infect Dis 2002;35:18-25
63. Srinivasan A, Song X, Ross T, et al. A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit. Infect Control Hosp Epidemiol 2002;23:424-428
64. Sample ML, Gravel D, Oxley C, et al. An outbreak of vancomycin-resistant enterococci in a hematology-oncology unit: control by patient cohorting and terminal cleaning of the environment. Infect Control Hosp Epidemiol 2002;23:468-470
65. MacIntyre CR, Empson M, Boardman C, et al. Risk factors for colonization with vancomycin-resistant enterococci in a Melbourne hospital. Infect Control Hosp Epidemiol 2001;22:624-629
66. Tornieporth NG, Roberts RB, John J, et al. Risk factors associated with vancomycin-resistant Enterococcusfaecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767-772
67. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant enterococcus. Emerg Infect Dis 2002;8:802-807
68. Loeb M, Salama S, Armstrong-Evans M, et al. A case-control study to detect modifiable risk factors for colonization with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1999;20:760-763
69. Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135:175-183
70. Moulin F, Dumontier S, Saulnier P, et al. Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. Clin Microbiol Infect 1996;2:192-201
71. Husni R, Hachem R, Hanna H, Raad I. Risk factors for vancomycin-resistant enterococcus (VRE) infection in colonized patients with cancer. Infect Control Hosp Epidemiol 2002;23:102-103
72. Harris AD, Samore MH, Lipsitch M, et al. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis 2002;34:1558-1563
73. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46:1619-1628
74. Empey KM, Rapp RP, Evans ME. The effect of an antimicrobial formulary change on hospital resistance patterns. Pharmacotherapy 2002;22:81-87
75. May AK, Melton SM, McGwin G, et al. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock 2000;14:259-264
76. Morgan AS, Brennan PJ, Fishman NO. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Ann Pharmacother 1997;31:970-973
77. Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycin-resistant Enterococcus in health care facilities in a region. N Engl J Med 2001;344:1427-1433
78. Siddiqui AH, Harris AD, Hebden J, et al. The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide. Am J Infect Control 2002;30:40-43
79. Austin DJ, Bonten MJ, Weinstein RA, et al. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci 1999;96:6908-6913
80. Garrison RN, Fry DE, Berberich S, Polk HC Jr. Enterococcal bacteremia: clinical implications and determinants of death. Ann Surg 1982;196:43-47
81. Hoge CW, Adams J, Buchanan B, Sears SD. Enterococcal bacteremia: to treat or not to treat, a reappraisal. Rev Infect Dis 1991;13:600-605
82. Caballero-Granado FJ, Becerril B, Cuberos L, et al. Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia. Clin Infect Dis 2001;32:587-594
83. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcusfaecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-670
84. Suppola JP, Kuikka A, Vaara M, Valtonen VV. Comparison of risk factors and outcome in patients with Enterococcusfaecalis vs Enterococcusfaecium bacteraemia. Scand J Infect Dis 1998;30:153-157
85. Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234-1239
86. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis 2002;34:922-929
87. Lucas GM, Lechtzin N, Puryear DW, et al. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998;26:1127-1133
88. Garbutt JM, Ventrapragada M, Littenberg B, et al. Association between resistance to vancomycin and death in cases of Enterococcusfaecium bacteremia. Clin Infect Dis 2000;30: 466-472
89. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318-323
90. Cetinkaya Y, Falk P, Mayhall GC. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;14:686-707
91. Murray BE. Vancomycin-resistant enterococci. Am J Med 1997;102:284-293
92. Westenfelder GO, Paterson PY, Reisberg BE, et al. Vancomycin-streptomycin synergism in enterococcal endocarditis. JAMA 1973;223:37-40
93. Costa Y, Galimand M, Leclercq R, et al. Characterization of the chromosomal aac(6′)-Ii gene specific for Enterococcusfaecium. Antimicrob Agents Chemother 1993;37:1896-1903
94. Tsai SF, Zervos MJ, Clewell DB, et al. A new high-level gentamicin resistance gene, aph(2″)-Id, in Enterococcus spp. Antimicrob Agents Chemother 1998;42:1229-1232
95. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995;274: 1706-1713
96. Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000;31:586-589
97. Lautenbach E, Schuster MG, Bilker WB, et al. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998;27:1259-1265
98. Hayden MK, Koenig GI, Trenholme GM. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrob Agents Chemother 1994;38:1225-1229
99. Caron F, Gold HS, Wennersten CB, et al. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997;41:2749-2753
100. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001;33:1816-1823
101. Goff DA, Sierawski SJ. Clinical experience of quinupristindalfopristin for the treatment of antimicrobial-resistant grampositive infections. Pharmacotherapy 2002;22:748-758
102. Williamson JC, Glazier SS, Peacock JE Jr. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. Clin Neurol Neurosurg 2002;104:54-56
103. Summers M, Misenhimer GR, Antony SJ. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin. South Med J 2001;94:353-355
104. Raad I, Hachem R, Hanna H, et al. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001;45:3202-3204
105. Verma A, Dhawan A, Philpott-Howard J, et al. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin. J Antimicrob Chemother 2001;47:105-108
106. Carretto E, Barbarini D, Locatelli F, et al. Vancomycin-resistant Enterococcusfaecium infection in three children given allogeneic hematopoietic stem cell transplantation: clinical and microbiologic features. Haematologica 2000;85:1158-1164
107. Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46:1319-1324
108. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44:251-261
109. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999;44(suppl A):37-46
110. Mutnick AH, Biedenbach DJ, Turnidge JD, et al. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002;43:65-73
111. Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur J Clin Microbiol Infect Dis 2002;21:491-498
112. Till M, Wixson RL, Pertel PE. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcusfaecium. Clin Infect Dis 2002;34:1412-1414
113. Steinmetz MP, Vogelbaum MA, De Georgia MA, et al. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 2001;29:2383-2385
114. Bailey EM, Faber MD, Nafziger DA. Linezolid for treatment of vancomycin-resistant enterococcal peritonitis. Am J Kidney Dis 2001;38:E20
115. Babcock HM, Ritchie DJ, Christiansen E, et al. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32:1373-1375
116. Stefani S, Mezzatesta ML, Tempera G, et al. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy. Clin Microbiol Infect 2002;8:368-372
117. Fang CT, Chang SC, Chen YC, et al. In vitro activity of linezolid against clinical gram-positive bacterial isolates from Taiwan: an area with a high prevalence of antibiotic resistance. Int J Antimicrob Agents 2001;18:267-270
118. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcusfaecium resistant to linezolid. Lancet 2001;357:1179
119. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346:867-869
120. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002;42:137-139
121. Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002;34: 695-698
122. Monson T, Schichman SA, Zent CS. Linezolid-induced pure red blood cell aplasia. Clin Infect Dis 2002;35:E29-31
123. Waldrep TW, Skiest DJ. Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy 2002;22:109-112
124. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002;46:2723-2726
125. Wise R, Andrews JM, Ashby JP. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001;48:563-567
126. Schouten MA, Voss A, Hoogkamp-Korstanje JA. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group. Antimicrob Agents Chemother 1999;43:2542-2546
127. Arthur M, Depardieu F, Reynolds P, et al. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother 1999;43:1875-1880
128. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000;44:2225-2229